NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









miRecule, Inc.

miRecule, Inc.

Private
Gaithersburg, MarylandHealthcare & Life Scienceshttps://mirecule.com/

Last Round

Series A

Jul 14, 2024

Total Funding Raised

$38.56M

Company Overview

miRecule, Inc. is a biotechnology company developing RNA-based therapies for cancer and muscular dystrophy using its proprietary DREAmiR platform to create highly tailored therapeutics.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Application

Keywords

RNA therapeuticsantibody-RNA conjugateARCdrug discovery platformprecision medicinegenomicsAI drug discoverybiotechtargeted therapymicroRNAbiopharmain silico drug discoverytherapeutic pipelinedrug licensing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

miRecule, Inc. Comparables

Compare miRecule, Inc. with similar companies based on industry and business-model similarity.

miRecule, Inc. comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Avidity Biosciences
80%
Epicrispr Biotechnologies
79%
Novartis
79%

miRecule, Inc. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJul 14, 2024
StrategicOct 4, 2022
GrantSep 29, 2022
GrantFeb 28, 2022
GrantMay 27, 2021
Seed
May 27, 2021

Key People

Founding team and executive leadership

Anthony Saleh

Co-founder And CEO

Founding Team

Dave Lemus

Chief Operating Officer Chief Financial Officer Board Member

Executive Team

miRecule, Inc. Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 14, 2024

    Completed a Series A funding round.

  • Aug 10, 2020

    $1.76M grant received from the National Cancer Institute.

miRecule, Inc. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

miRecule, Inc. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about miRecule, Inc.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersGaithersburg, Maryland
Employee Range12
Year Founded2016
Last FundingJul 14, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.